Palisade Bio Q1 net loss widens on higher R&D costs

Palisade Bio

12/05/2026 21:26

Overview

US biopharma firm's Q1 net loss widened on higher R&D and administrative expenses

Company advanced PALI-2108 with positive Phase 1b data; Phase 2 trials planned for 2026-2027

Company ended Q1 with $132.6 mln cash, expects funding to cover key clinical milestones

Outlook

Company expects to submit IND for Phase 2 UC trial in 2Q 2026

Phase 2 UC trial initiation targeted for Q3 2026

Company says cash on hand is sufficient through key clinical readouts in 2027 and 2028

Result Drivers

R&D SPENDING - Higher research and development expenses driven by increased employee costs, clinical trial activity for PALI-2108, and manufacturing spending

CLINICAL ADVANCEMENT - Positive Phase 1b data for PALI-2108 supported continued development and investment in Phase 2 trials

ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher employee-related costs and professional fees

Company press release: ID:nGNX7b9nby

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.05
Q1 Net Income
-$9.60 mln
Q1 Operating Expenses
$10.75 mln
Q1 Operating Income
-$10.75 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Palisade Bio Inc is $7.50, about 286.6% above its May 11 closing price of $1.94

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)